Gilles Guillemin
DEPARTMENT OF BIOMEDICAL SCIENCES
Macquarie University
Australia
Biography
Prof Guillemin’s team is one of the world’s leading research groups studying neuroactive (toxic or protective or immunomodulator) metabolites deriving from tryptophan metabolism and their involvement in several neurodegenerative diseases. Over the last two decades, he demonstrated the importance of this pathway in multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, which has opened numerous new promising research avenues and has translated to important new prognostic and therapeutic strategies. Through their important international and national collaborative network, Prof Guillemin and his research team have extended their research to other diseases such as Parkinson’s disease, suicide, depression, autism, schizophrenia breast cancers and brain tumours.
Research Interest
Involvement of the kynurenine pathway in neurodegenerative diseases; Identification of biomarker for progression, severity and response to treatment for neurodegenerative diseases; Development of the new therapeutic strategies targeting the kynurenine pathway for neurodegenerative diseases and cancers; Identification of environmental factors associated with sporadic motor neuron disease (biotoxins and chemicals). Natural products and neuroprotection
Publications
-
Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. Journal of neurochemistry. 2001 Aug 15;78(4):842-53.
-
Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. Journal of leukocyte biology. 2004 Mar 1;75(3):388-97.
-
Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M. Anendogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011 Oct 13;478(7368):197.
